

1 **SARS-CoV-2 Seroprevalence Among Antenatal Clinic Attendees in Kingston, Jamaica,**
2 **September-November 2020**

3

4 Te'Anne Chisolm^{1,#}, Jerome P. Walker^{1,#}, Ynolde Leys¹, Tiffany R. Butterfield¹, Candice
5 Medley² Tamara K. Thompson³, Glendee Reynolds-Campbell¹, Willem H. Mulder⁴, Michelle
6 Campbell Mitchell², Joshua J. Anzinger^{1,*}

7

8 ¹The University of the West Indies, Department of Microbiology, Kingston, Jamaica, West
9 Indies

10 ²The University of the West Indies, Department of Obstetrics and Gynaecology, Kingston,
11 Jamaica, West Indies

12 ³The University of the West Indies, Department of Medicine, Kingston, Jamaica, West Indies

13 ⁴The University of the West Indies, Department of Chemistry, Kingston, Jamaica, West Indies

14

15 [#]These authors contributed equally

16

17 *Address correspondence to Joshua Anzinger, Department of Microbiology, The University of
18 the West Indies, Mona, Kingston 7, Jamaica. E-mail: joshua.anzinger@uwimona.edu.jm Phone:
19 +1 876-977-2206

20

21 Running Head: SARS-CoV-2 seroprevalence in Kingston, Jamaica

22

23 Keywords: SARS-CoV-2, seroprevalence, antibody test, pregnancy, Jamaica

24

- 25 Number of Figures: 2
- 26 Number of Tables: 1
- 27 Number of Supplementary Files: 1 (Supplemental Methods)
- 28
- 29 Abstract Word Count: 142
- 30 Text Word Count: 1408

31 **Abstract**

32 SARS-CoV-2 seroprevalence in an antenatal population in Kingston, Jamaica was assessed for
33 September-November 2020 in a repeated cross-sectional study using the Abbott Architect
34 SARS-CoV-2 IgG assay. After adjusting for test performance, seroprevalence was 6.9% for
35 September, 16.9% for October, and 24.0% for November. Of the 37 pregnant women testing
36 SARS-CoV-2 IgG positive, only 3 were symptomatic. One symptomatic woman testing SARS-
37 CoV-2 IgG positive had multiple co-morbidities and succumbed to COVID-19 pneumonia. Up to
38 January 31, 2021, 8 women identified as SARS-CoV-2 IgG positive delivered, all without
39 complications. Comparison of test adjusted seroprevalence data with cumulative PCR-confirmed
40 COVID-19 cases within the Kingston Metropolitan Area indicated that as many as 44.4 times
41 more people were infected with SARS-CoV-2 than identified with PCR testing. These findings
42 provide the first evidence for the extent of SARS-CoV-2 infections in Jamaica and will inform
43 future SARS-CoV-2 testing strategies.

44 The first confirmed COVID-19 cases in the Caribbean occurred in March 2020, with the first
45 confirmed case of COVID-19 in Jamaica occurring on March 10, 2020.¹ Subsequent to the
46 introduction of SARS-CoV-2 in Jamaica, governmental restrictions were imposed that included
47 school closures (March 13, 2020), closure of international borders (March 21, 2020), and
48 implementation of daily island-wide curfews (April 1, 2020). Restrictions were eased on June 1,
49 2020 to reopen international borders, but up to January 2021 most schools have remained closed
50 (virtual schooling) and island-wide curfews remain in effect. Up to August 2020, confirmed
51 cases of COVID-19 in Jamaica remained below 1,000 and only 10 deaths were reported for the
52 entire population of approximately 2.7 million people. Several weeks after the Emancipation Day
53 (August 1, 2020) and Independence Day (August 6, 2020) holidays COVID-19 PCR-confirmed
54 cases increased rapidly, followed by increased COVID-19 deaths, and on August 30, 2020 the
55 Government of Jamaica declared COVID-19 community transmission. Up to January 31, 2021
56 there have been 15,973 confirmed COVID-19 cases and 353 deaths in Jamaica.

57 Although it is clear that SARS-CoV-2 community transmission in Jamaica has led to a great
58 increase in COVID-19 cases and deaths, it remains unknown as to the extent of transmission, as
59 even in the most resourced countries most cases are not identified.^{2,3} SARS-CoV-2
60 seroprevalence studies can determine the extent of transmission within a population that can
61 inform the public health response. This information can indicate whether the amount of testing is
62 adequate and also informs transmission dynamics due to persons likely having some degree of
63 immunity that have been infected recently.⁴

64 Samples collected from pregnant women seeking routine antenatal care are commonly used to
65 provide prevalence estimates of disease, as is done in some sub-Saharan African countries to
66 determine HIV prevalence.⁵ More recently antenatal samples have been examined to provide a

67 prevalence estimate of SARS-CoV-2 infections.⁶ Residual serum samples from pregnant women
68 attending antenatal clinics provide a valuable tool to determine the extent of SARS-CoV-2
69 infections in a population and are also a unique population due to possible risks of infectious
70 disease not only to the pregnant woman but also to the fetus. Although SARS-CoV-2-infected
71 pregnant women are commonly asymptomatic,⁷⁻⁹ symptomatic pregnant women were recently
72 shown to be at increased risk of severe disease.¹⁰ Thus far, studies of COVID-19 in pregnancy
73 show that poor outcomes are uncommon for both the mother and child, and vertical transmission
74 appears to be rare.¹¹ COVID-19 studies in antenatal populations are limited, however, which has
75 led several experts to promote increased COVID-19 surveillance and research of pregnant
76 women.¹²

77 In this repeated cross-sectional study, we determined the presence of SARS-CoV-2 IgG in all
78 University Hospital of the West Indies (UHWI) antenatal residual serum samples submitted
79 during September-November 2020. The UHWI, located in Kingston, Jamaica, is the largest
80 tertiary hospital in the country with approximately 1,600 deliveries each year. Most pregnant
81 women attending the UHWI antenatal clinic reside in the Kingston Metropolitan Area, the most
82 populous metropolitan area of Jamaica that is primarily within the parishes of Kingston and St
83 Andrew. UHWI antenatal samples are routinely received in the Virology Laboratory of the
84 University of the West Indies Department of Microbiology for HIV testing. A total of 249 unique
85 patient samples (i.e., no patient was tested more than once) were tested for SARS-CoV-2 IgG.
86 This study was approved by the UWI Mona Campus Research Ethics Committee (ECP 244
87 20/21).

88 SARS-CoV-2 IgG testing was determined via the Abbott chemiluminescence immunoassay
89 (CMIA) using an Architect *i*2000SR instrument. The Abbott Architect SARS-CoV-2 IgG assay

90 is CE marked and is EUA authorized by the FDA. Previous assessment of this assay in the adult
91 Jamaican population did not include pregnant women in sensitivity analysis, but 20 samples from
92 pregnant women were tested to determine specificity with one sample testing false positive (2.45
93 S/CO).¹³ An additional 32 antenatal samples collected in September-December 2019 (prior to
94 SARS-CoV-2 introduction into Jamaica) were tested, with no samples testing SARS-CoV-2 IgG
95 positive using the manufacturer's recommended cutoff of ≥ 1.4 S/CO (Figure 1A). Including the
96 previous data with this data resulted in a specificity of 98.08% (95% CI: 89.74-99.95%) when
97 using the manufacturer's recommended cutoff of ≥ 1.4 S/CO that maximizes specificity but
98 underestimates true positives.^{14,15} Lowering the cutoff value from ≥ 1.4 S/CO to ≥ 0.4 S/CO
99 resulted in one additional false positive sample (0.64 S/CO) for a specificity of 96.15% (95% CI:
100 86.79-99.53%). To determine the sensitivity of the Architect SARS-CoV-2 IgG assay for
101 pregnant Jamaican women, we collected convalescent blood samples from SARS-CoV-2 PCR-
102 confirmed pregnant women and tested sera for the presence of SARS-CoV-2 IgG (Figure 1B).
103 Identification of SARS-CoV-2 PCR-confirmed pregnant women at the UHWI was challenging
104 as most SARS-CoV-2 infected women were asymptomatic (see below). Of the 10 SARS-CoV-2
105 PCR confirmed pregnant women recruited, 8 tested positive (≥ 0.4 S/CO) for an overall
106 sensitivity of 80% (95% CI: 44.39-97.48%).

107 Samples from all women attending the UHWI antenatal clinic from September-November
108 2020 were tested, and 17 samples collected from the first week of March 2020 were also tested
109 (Figure 2). The percentage of samples testing positive (≥ 0.4 S/CO) for each month was: 0.0%
110 (0/17) in March, 9.1% (7/77) in September, 16.7% (13/78) in October, and 22.1% (17/77) in
111 November (Table 1). Of the 37 women testing positive (≥ 0.4 S/CO), only 3 had a history of
112 COVID-19 symptoms, consistent with previous observations that most pregnant women infected

113 with SARS-CoV-2 remain asymptomatic.⁷⁻⁹ Only 8 of the 37 women testing positive (≥ 0.4
114 S/CO) had a SARS-CoV-2 PCR test up to the day of the sample collected that tested SARS-
115 CoV-2 IgG positive, of which 3 were SARS-CoV-2 PCR positive. Of the 3 symptomatic women,
116 2 were SARS-CoV-2 PCR-confirmed, with 1 woman requiring intubation and management in
117 the intensive care unit that subsequently demised. Of note the deceased patient was obese, with a
118 history of breast cancer, and was of advanced maternal age (>40 years of age). Of the 8 mothers
119 that delivered up to January 31, 2021, all neonates were born without complications with 2
120 deliveries occurring at late pre-term gestations. The distribution of ages was similar between
121 women testing SARS-CoV-2 IgG negative and SARS-CoV-2 IgG positive as determined by
122 Pearson's Chi-squared test ($p=0.164$). Antenatal samples received for the months of September-
123 November for 2018-2020 were similar (Pearson's Chi-Square test; $p=0.835$), indicating that
124 COVID-19 was unlikely to affect prenatal visit attendance during September-November 2020.

125 For samples testing ≥ 0.4 S/CO, median monthly values showed a decreasing trend
126 (Figure 2): 3.28 S/CO for September, 3.08 S/CO for October, and 2.08 S/CO for November (no
127 samples in March tested ≥ 0.4 S/CO), indicating that seroreversion was likely occurring as has
128 been reported previously for the Abbott Architect SARS-CoV-2 IgG assay.¹⁵⁻¹⁸ Crude
129 seroprevalences were adjusted for test performance alone and with adjustment for seroreversion
130 as described in the supplementary methods (Table 1). Adjusting for test performance only
131 resulted in SARS-CoV-2 prevalences of 6.9% in September, 16.9% in October, and 24.0% in
132 November. Adjusting for both test performance and seroreversion showed SARS-CoV-2
133 prevalences of 6.9% in September, 18.2% in October, and 28.5% in November.

134 Our data identifies an underappreciated prevalence of SARS-CoV-2 infections among
135 antenatal women in the Kingston Metropolitan Area and provides an approximation of the extent

136 of infections within the area. There were 2442, 3204, and 3590 cumulative confirmed COVID-19
137 cases in the parishes of Kingston and St Andrew in September, October, and November,
138 respectively (Ministry of Health and Wellness). Thus, of the 669,773 persons inhabiting the
139 parishes of Kingston and St Andrew (Statistical Institute of Jamaica, 2018), the percentage of the
140 population identified to be infected with SARS-CoV-2 via PCR and serology (with test
141 adjustment only), respectively, was 0.36% and 6.9% in September, 0.48% and 16.9% in October,
142 0.54% and 24.0% in November. This data indicates a 19.2-44.4-fold difference between
143 serological identification of persons infected compared to SARS-CoV-2 PCR-confirmed cases,
144 which is likely a slight underestimate due to seroreversion. The large disparity between SARS-
145 CoV-2 PCR confirmed cases and those identified by antibody in this study highlights the
146 difficulty of identifying SARS-CoV-2 cases with PCR testing, particularly in a resource-limited
147 setting, and the utility of SARS-CoV-2 antibody testing to approximate population exposure.

148 Although our study provides the first assessment of the extent of SARS-CoV-2 infections in
149 Jamaica, SARS-CoV-2 has not spread throughout the island uniformly, limiting our ability to
150 draw conclusions about the extent of virus infections throughout Jamaica. Future studies
151 examining additional populations in Jamaica will be informative to identify the extent of SARS-
152 CoV-2 circulation across the island.

153 Acknowledgements: As a Global Infectious Diseases Scholars, Ynolde Leys and Tiffany
154 Butterfield received mentored research training in the development of this manuscript. This
155 training was supported in part by the University at Buffalo Clinical and Translational Science
156 Institute award UL1TR001412 and the Global Infectious Diseases Research Training Program
157 award D43TW010919. The content is solely the responsibility of the authors and does not
158 necessarily represent the official views of the Clinical and Translational Science Institute or the
159 National Institutes of Health.

160

161 Financial Support: The University Hospital of the West Indies.

162

163 Disclosure: All authors declared no conflict of interest.

164


165 Authors' addresses: Te'Anne Chisholm, Jerome Walker, Ynolde Leys, Tiffany Butterfield,
166 Glendee Reynolds-Campbell, Joshua J. Anzinger, Department of Microbiology, The University
167 of the West Indies, Mona, Kingston, Jamaica, E-mails: tchis_31@hotmail.com,
168 Jerome.P.Walker@gmail.com, ynolde.leys@gmail.com, tiffany.butterfield@uwimona.edu.jm,
169 glendee.reynoldscampbell02@uwimona.edu.jm, joshua.anzinger@uwimona.edu.jm. Candice
170 Medley, Michelle Campbell Mitchell, Department of Obstetrics and Gynaecology, The
171 University of the West Indies, Mona, Kingston, Jamaica, E-mails: candicemedley@yahoo.com,
172 campbell.michelle.a@gmail.com. Tamara K Thompson, Department of Medicine, The
173 University of the West Indies, Kingston, Jamaica, E-mail: tamara.thompson@uwimona.edu.jm
174 Willem H Mulder, Department of Chemistry, The University of the West Indies, Kingston,
175 Jamaica, E-mail: willem.mulder@uwimona.edu.jm

176 **References**

- 177 1. Christie CDC, Thompson T, Webster-Kerr K, 2020. COVID-19 War Games in the
178 Caribbean—Round One. *[COVID] 1*:69-76
- 179 2. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J, 2020. Substantial
180 undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-
181 CoV-2). *Science 368*:489-493.
- 182 3. Wu SL et al., 2020. Substantial underestimation of SARS-CoV-2 infection in the United
183 States. *Nat Commun 11*: 4507.
- 184 4. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW,
185 Farnsworth CW, 2020. Clinical Performance of Two SARS-CoV-2 Serologic Assays. *Clin*
186 *Chem 66*:1055-1062.
- 187 5. Eaton JW, Rehle TM, Jooste S, Nkambule R, Kim AA, Mahy M, Hallett TB, 2014.
188 Recent HIV prevalence trends among pregnant women and all women in sub-Saharan
189 Africa: implications for HIV estimates. *AIDS 28*:S507.
- 190 6. Flannery DD et al., 2020. SARS-CoV-2 seroprevalence among parturient women in
191 Philadelphia. *Sci Immunol 5*: eabd5709.
- 192 7. Sutton D, Fuchs K, D’Alton M, Goffman D, 2020. Universal Screening for SARS-CoV-2
193 in Women Admitted for Delivery. *N Engl J Med 382*:2163-2164.
- 194 8. Khalil A, Hill R, Ladhani S, Pattison K, O’Brien P, 2020. Severe acute respiratory
195 syndrome coronavirus 2 in pregnancy: symptomatic pregnant women are only the tip of
196 the iceberg. *Am J Obstet Gynecol 223*:296-297.
- 197 9. Delahoy MJ et al., 2020. Characteristics and Maternal and Birth Outcomes of Hospitalized
198 Pregnant Women with Laboratory-Confirmed COVID-19 - COVID-NET, 13 States,

- 199 March 1-August 22, 2020. *MMWR Morb Mortal Wkly Rep* 69:1347-1354.
- 200 10. Zambrano LD et al., 2020. Update: Characteristics of Symptomatic Women of
201 Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy
202 Status - United States, January 22-October 3, 2020. *MMWR Morb Mortal Wkly Rep*
203 69:1641-1647.
- 204 11. Wastnedge EAN, Reynolds RM, van Boeckel SR, Stock SJ, Denison F, Maybin JA,
205 Critchley HOD, 2021. Pregnancy and COVID-19. *Physiol Rev* 101:303-318.
- 206 12. Buekens P, Alger J, Bréart G, Cafferata ML, Harville E, Tomasso G, 2020. A call for
207 action for COVID-19 surveillance and research during pregnancy. *Lancet Glob Heal*
208 8:e877-e878.
- 209 13. Butterfield TR, Bruce-Mowatt A, Phillips YZR, Brown N, Francis K, Brown J, Taylor D,
210 Bruce CA, McGrowder D, Wharfe G. Assessment of Commercial SARS-CoV-2 Antibody
211 Assays, Jamaica. *medRxiv*. Published online September 29, 2020.
- 212 14. Eyre DW et al.,. Stringent thresholds for SARS-CoV-2 IgG assays result in under-
213 detection of cases reporting loss of taste/smell. *medRxiv*. Published online January 1,
214 2020.
- 215 15. Buss LF et al., 2021. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon
216 during a largely unmitigated epidemic. *Science* 371:288-292.
- 217 16. Lumley SF et al., 2021. The duration, dynamics and determinants of SARS-CoV-2
218 antibody responses in individual healthcare workers. *Clin Infect Dis* Published online
219 January 2021.
- 220 17. Muecksch F et al., 2020. Longitudinal analysis of serology and neutralising antibody
221 levels in COVID19 convalescents. *J Infect Dis*. Published online November 2020.

222 18. Maine GN, Lao KM, Krishnan SM, Afolayan-Oloye O, Fatemi S, Kumar S, VanHorn L,
223 Hurand A, Sykes E, Sun Q, 2020. Longitudinal characterization of the IgM and IgG
224 humoral response in symptomatic COVID-19 patients using the Abbott Architect. *J Clin*
225 *Virol* 133:104663.
226




227

228 Figure 1. Architect SARS-CoV-2 IgG assay index values (S/CO) for (A) pre-pandemic 2019

229 antenatal samples and (B) convalescent sera from SARS-CoV-2 PCR confirmed pregnant

230 women. The dashed lines indicate the manufacturer's cutoff value (≥ 1.4 S/CO) and the cutoff

231 value defined in this study for a positive test result (≥ 0.4 S/CO).



232

233 Figure 2. Distribution of SARS-CoV-2 IgG index values (S/CO) for tested residual antenatal
 234 serum samples. The dashed lines indicate the manufacturer's cutoff value (≥ 1.4 S/CO) and the
 235 cutoff value defined in this study for a positive test result (≥ 0.4 S/CO).

Table 1
Prevalence of SARS-CoV-2 infections in pregnant women

Month	Crude Prevalence (≥ 1.4 S/CO)	Crude Prevalence (≥ 0.4 S/CO)	Test Adjusted Prevalence	Test and Seroreversion Adjusted Prevalence
March	0.0% (0/17)	0.0 (0/17)	—	—
September	7.8% (6/77)	9.1 (7/77)	6.9	6.9
October	14.1% (11/78)	16.7 (13/78)	16.9	18.2
November	13.0 (10/77)	22.1 (17/77)	24.0	28.5

236